# EDGAR Filing Document

**Accession Number:** 0002096997
**File Stem:** 0001104659-26-046276
**Filing Date:** 2026-4
**Character Count:** 7480
**Document Hash:** da34decf58bea38b3adf1a13145b9341
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-046276.hdr.sgml**: 20260422

**ACCESSION NUMBER**: 0001104659-26-046276

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260420

**FILED AS OF DATE**: 20260422

**DATE AS OF CHANGE**: 20260422

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- **CENTRAL INDEX KEY:** 0002080343

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 1231
- **LEGAL ENTITY IDENTIFIER:** 2549003BT1XS3SE3E448

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43233
- **FILM NUMBER:** 26881177

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 7 KUNLUNSHAN ROAD
- **STREET 2:** ECON. AND TECHNOLOGICAL DEVELOPMENT ZONE
- **CITY:** LIANYUNGANG
- **NON US STATE TERRITORY:** JIANGSU PROVINCE
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86-21-61053532

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 7 KUNLUNSHAN ROAD
- **STREET 2:** ECON. AND TECHNOLOGICAL DEVELOPMENT ZONE
- **CITY:** LIANYUNGANG
- **NON US STATE TERRITORY:** JIANGSU PROVINCE
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Jiangsu Hengrui Pharmaceuticals Co., Ltd
- **DATE OF NAME CHANGE:** 20250806
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kailera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002096997
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 508-440-9475

**MAIL ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<br><sub>(Last) (First) (Middle)</sub><br>7 KUNLUNSHAN RD, ECON. & TECH. DEV. ZONE<br><sub>(Street)</sub><br>LIANYUNGANG, CHINA 222000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Kailera Therapeutics, Inc. [ KLRA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-04-20 |  | C |  | 9477719 | A | <sup>(2)</sup> | 9477719 | D |  |
| Common Stock | 2026-04-20 |  | C |  | 2034133 | A | <sup>(2)</sup> | 2034133 | D |  |
| Common Stock |  |  |  |  |  |  |  | 1 | I | By Hengrui (USA) Ltd.<sup>(1)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A-2 convertible preferred stock | <sup>(2)</sup> | 2026-04-20 |  | C |  |  | 4968789 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 9477719 | $0 | 0 | D |  |
| Series A-2 convertible non-voting preferred stock | <sup>(2)</sup> | 2026-04-20 |  | C |  |  | 708814 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 2034133 | $0 | 0 | D |  |

---

### Footnotes:

(1) The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

(2) The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

**Signature:** Jiangsu Hengrui Pharmaceuticals Co., Ltd. /s/ Lau Kin Chun, Financial Controller, on behalf of Jiangsu Hengrui Pharmaceuticals Co., Ltd.  
**Date:** 2026-04-22

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**